The Mulligan Law Firm is Evaluating Raptiva® (Efalizumab) Alleged Injury Cases
The Mulligan Law Firm is Evaluating Raptiva® (Efalizumab) Alleged Injury Cases The Mulligan Law Firm announces that it is evaluating and investigating cases where the usage of the drug Raptiva® has allegedly led to a rare brain infection known as Progressive Multifocal Leukoencephalopathy (PML), a very serious and almost always fatal viral brain infection. Dallas, TX (PRWEB) June 18, 2009 -- The Mulligan Law Firm (http://www.mulliganlaw.com) is evaluating alleged injuries related to the use of the drug Raptiva®. Raptiva®, a ps
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 313
- Bankruptcy 44
- Business 135
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 58
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4